3rd Quarter - Report — CYSTIC FIBROSIS FOUNDATION for CYSTIC FIBROSIS FOUNDATION (2010)

Firm

CYSTIC FIBROSIS FOUNDATION

Client

CYSTIC FIBROSIS FOUNDATION

Income

—

Expenses

$55,593

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Clinical research S. 1675 "Improving Access to Clinical Trials Act" passage & implementation; Health care reform & implementation including B. Marshalls PCORI nomination, comment submissions; FDA funding & processes; NIH funding & processes; CMS coverage decisions including: home IV & DME; 340B Drug Pricing Program; FDA drug approval process

Lobbyist	Covered position, as disclosed
ERIC CHAMBERLAIN	—
MARY B DWIGHT	Legislative Correspondent; Legislative Assistant
STEPHANIE KRENRICH	Sr. Leg. Asst.; Leg. Asst.; Leg. Aide; Leg. Corr.
C RICHARD MATTINGLY New	—
JASON RANVILLE	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Social Security Administration (SSA)

Bills named: S. 1675 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.